Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …
FPB Kroon, A Najm, A Alunno, JW Schoones… - Annals of the …, 2022 - ard.bmj.com
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States
Objectives To investigate outcomes of Coronavirus Disease-2019 (COVID-19) in patients
with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes …
with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes …
[HTML][HTML] Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР …
ЕЛ Насонов, БС Белов, АМ Лила… - Научно …, 2021 - cyberleninka.ru
Представлены материалы Российской базы данных НИИР/АРР-С0УГО-19,
включавшей взрослых (старше 18 лет) пациентов с иммуновоспалительными …
включавшей взрослых (старше 18 лет) пациентов с иммуновоспалительными …
Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses
Abstract Outcomes of COrona VIrus Disease-19 (COVID-19) in patients with rheumatic
diseases (RDs) reported in various studies are heterogenous owing to the influence of age …
diseases (RDs) reported in various studies are heterogenous owing to the influence of age …
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome
Initial case series of small number of patients at the beginning of the pandemic reported a
rather guarded prognosis for Behçet's syndrome (BS) patients infected with SARS-CoV-2. In …
rather guarded prognosis for Behçet's syndrome (BS) patients infected with SARS-CoV-2. In …
COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review
A Rodriguez-Pla, HR Vikram, V Khalid… - Rheumatology …, 2021 - Springer
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on
rituximab and prednisone, presented to the hospital with worsening cough and shortness of …
rituximab and prednisone, presented to the hospital with worsening cough and shortness of …
COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease
Objectives To evaluate the impact of familial Mediterranean fever (FMF) features on the
clinical course and outcomes of coronavirus disease 2019 (COVID-19) and clinical course of …
clinical course and outcomes of coronavirus disease 2019 (COVID-19) and clinical course of …
Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022: Analysis of the JCR COVID-19 registry in Japan
Y Kashiwado, Y Kimoto, K Oku… - Modern …, 2024 - academic.oup.com
Objectives The aim is to evaluate the treatment and prognosis of coronavirus disease 2019
(COVID-19) according to the time of onset and dominant strain in patients with rheumatic …
(COVID-19) according to the time of onset and dominant strain in patients with rheumatic …
SARS-CoV-2 seroprevalence in patients with autoimmune rheumatic diseases versus family controls: a multi-city cross-sectional survey
There is uncertainty regarding the effect of the SARS-CoV-2 infection on patients with
autoimmune rheumatic diseases (AIRD) who are on immunosuppressive drugs. We did a …
autoimmune rheumatic diseases (AIRD) who are on immunosuppressive drugs. We did a …
Preferences of inflammatory arthritis patients for biological disease-modifyingantirheumatic drugs in the first 100 days of the COVID-19 pandemic
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation
among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after …
among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after …